AAAAAA

   
Results: 1-25 | 26-50 | 51-64
Results: 1-25/64
PROPHYLACTIC ISOLATED LIMB PERFUSION FOR LOCALIZED, HIGH-RISK LIMB MELANOMA - RESULTS OF A MULTICENTER RANDOMIZED PHASE-III TRIAL
Authors: KOOPS HS VAGLINI M SUCIU S KROON BBR THOMPSON JF GOHL J EGGERMONT AMM DIFILIPPO F KREMENTZ ET RUITER D LEJEUNE FJ
Citation: Hs. Koops et al., PROPHYLACTIC ISOLATED LIMB PERFUSION FOR LOCALIZED, HIGH-RISK LIMB MELANOMA - RESULTS OF A MULTICENTER RANDOMIZED PHASE-III TRIAL, Journal of clinical oncology, 16(9), 1998, pp. 2906-2912
MITOXANTRONE VERSUS DAUNORUBICIN IN INDUCTION-CONSOLIDATION CHEMOTHERAPY - THE VALUE OF LOW-DOSE CYTARABINE FOR MAINTENANCE OF REMISSION, AND AN ASSESSMENT OF PROGNOSTIC FACTORS IN ACUTE MYELOID-LEUKEMIA IN THE ELDERLY - FINAL REPORT OF THE LEUKEMIA COOPERATIVE GROUP OF THE ANIZATION-FOR-THE-RESEARCH-AND-TREATMENT-OF-CANCER AND THE DUTCH-BELGIAN HEMATOONCOLOGY COOPERATIVE HOVON GROUP RANDOMIZED PHASE-III STUDY AML-9
Authors: LOWENBERG B SUCIU S ARCHIMBAUD E HAAK H STRYCKMANS P DECATALDO R DEKKER AW BERNEMAN ZN THYSS A VANDERLELIE J SONNEVELD P VISANI G FILLET G HAYAT M HAGEMEIJER A SOLBU G ZITTOUN R
Citation: B. Lowenberg et al., MITOXANTRONE VERSUS DAUNORUBICIN IN INDUCTION-CONSOLIDATION CHEMOTHERAPY - THE VALUE OF LOW-DOSE CYTARABINE FOR MAINTENANCE OF REMISSION, AND AN ASSESSMENT OF PROGNOSTIC FACTORS IN ACUTE MYELOID-LEUKEMIA IN THE ELDERLY - FINAL REPORT OF THE LEUKEMIA COOPERATIVE GROUP OF THE ANIZATION-FOR-THE-RESEARCH-AND-TREATMENT-OF-CANCER AND THE DUTCH-BELGIAN HEMATOONCOLOGY COOPERATIVE HOVON GROUP RANDOMIZED PHASE-III STUDY AML-9, Journal of clinical oncology, 16(3), 1998, pp. 872-881
AUTOLOGOUS STEM-CELL TRANSPLANTATION (ASCT) FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME AND SECUNDARY ACUTE MYELOID-LEUKEMIA
Authors: DEWITTE T VANBIEZEN A HERMANS J SUCIU S DARDENNE M LABAR B ARCHIMBAUD E AUL C SELLESLAG D FERRANT A MELONI G MAURI SB CARELLA A LAPORTE J DEMUYNCK H NIEDERWIESER D GRATWOHL A APPERLEY J
Citation: T. Dewitte et al., AUTOLOGOUS STEM-CELL TRANSPLANTATION (ASCT) FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME AND SECUNDARY ACUTE MYELOID-LEUKEMIA, Bone marrow transplantation, 21, 1998, pp. 37-37
METAANALYSIS OF RANDOMIZED TRIALS COMPARING AUTOLOGOUS BMT (ABMT) VS CHEMOTHERAPY (CT) OR ABMT VS NO FURTHER TREATMENT (NFT) AS POSTREMISSION TREATMENT IN ADULT AML PATIENTS
Authors: SUCIU S
Citation: S. Suciu, METAANALYSIS OF RANDOMIZED TRIALS COMPARING AUTOLOGOUS BMT (ABMT) VS CHEMOTHERAPY (CT) OR ABMT VS NO FURTHER TREATMENT (NFT) AS POSTREMISSION TREATMENT IN ADULT AML PATIENTS, Bone marrow transplantation, 21, 1998, pp. 43-43
RESULTS OF POSTCONSOLIDATION TREATMENT FOR PATIENTS LESS-THAN 51 YEARS OF AGE WITH AML IN FIRST CR IN THE AML 10 STUDY OF THE LEUKEMIA COOPERATIVE GROUP OF THE EORTC AND GIMEMA
Authors: KEATING S SUCIU S MANDELLI F DEWITTE T ZITTOUN R ARCHIMBAUD E RESEGOTTI L MELONI G FAZI P DARDENNE M WILLEMZE R
Citation: S. Keating et al., RESULTS OF POSTCONSOLIDATION TREATMENT FOR PATIENTS LESS-THAN 51 YEARS OF AGE WITH AML IN FIRST CR IN THE AML 10 STUDY OF THE LEUKEMIA COOPERATIVE GROUP OF THE EORTC AND GIMEMA, Bone marrow transplantation, 21, 1998, pp. 44-44
AUTOLOGOUS STEM-CELL TRANSPLANTATION (ASCT) FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME AND SECUNDARY ACUTE MYELOID-LEUKEMIA, ON BEHALF OF THE MDS STUDY-GROUP OF THE EBMT CLWP AND THE EORTC-LCG
Authors: DEWITTE T VANBIEZEN A HERMANS J SUCIU S DARDENNE M LABAR B ARCHIMBAUD E AUL C SELLESLAG D FERRANT A MELONI G MAURI SB CARELLA A LAPORTE J DEMUYNCK H NIEDERWIESER D GRATWOHL A APPERLEY J
Citation: T. Dewitte et al., AUTOLOGOUS STEM-CELL TRANSPLANTATION (ASCT) FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME AND SECUNDARY ACUTE MYELOID-LEUKEMIA, ON BEHALF OF THE MDS STUDY-GROUP OF THE EBMT CLWP AND THE EORTC-LCG, Bone marrow transplantation, 21, 1998, pp. 750-750
CLINICAL-SIGNIFICANCE OF MINIMAL RESIDUAL DISEASE IN CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA
Authors: CAVE H TENBOSCH JV SUCIU S GUIDAL C WATERKEYN C OTTEN J BAKKUS M THIELEMANS K GRANDCHAMP B VILMER E
Citation: H. Cave et al., CLINICAL-SIGNIFICANCE OF MINIMAL RESIDUAL DISEASE IN CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA, The New England journal of medicine, 339(9), 1998, pp. 591-598
THE INFLUENCE OF HLA-MATCHED SIBLING DONOR AVAILABILITY ON TREATMENT OUTCOME FOR PATIENTS WITH AML - AN ANALYSIS OF THE AML 8A STUDY OF THEEORTC-LEUKEMIA-COOPERATIVE-GROUP AND GIMEMA
Authors: KEATING S DEWITTE T SUCIU S WILLEMZE R HAYAT M LABAR B RESEGOTTI L FERRINI PR CARONIA F DARDENNE M SOLBU G PETTI MC VEGNA ML MANDELLI F ZITTOUN RA
Citation: S. Keating et al., THE INFLUENCE OF HLA-MATCHED SIBLING DONOR AVAILABILITY ON TREATMENT OUTCOME FOR PATIENTS WITH AML - AN ANALYSIS OF THE AML 8A STUDY OF THEEORTC-LEUKEMIA-COOPERATIVE-GROUP AND GIMEMA, British Journal of Haematology, 102(5), 1998, pp. 1344-1353
AUTOLOGOUS STEM-CELL TRANSPLANTATION (ASCT) FOR PATIENTS WITH POOR-RISK MDS AND SECUNDARY AML (SAML)
Authors: DEWITTE T SUCIU S VERHOEF G LABAR B ARCHIMBAUD E AUL C SELLESLAG D FERRANT A WIJERMANS P MANDELLI F AMADORI S JEHN U MUUS P DEMUYNCK H DARDENNE M ZITTOUN R WILLEMZE R GRATWOHL A APPERLEY J
Citation: T. Dewitte et al., AUTOLOGOUS STEM-CELL TRANSPLANTATION (ASCT) FOR PATIENTS WITH POOR-RISK MDS AND SECUNDARY AML (SAML), British Journal of Haematology, 102(1), 1998, pp. 282-282
COST-EFFECTIVENESS AND QUALITY-OF-LIFE ASSESSMENT OF GM-CSF AS AN ADJUNCT TO INTENSIVE REMISSION INDUCTION CHEMOTHERAPY IN ELDERLY PATIENTSWITH ACUTE MYELOID-LEUKEMIA
Authors: UYLDEGROOT CA LOWENBERG B VELLENGA E SUCIU S WILLEMZE R RUTTEN FFH
Citation: Ca. Uyldegroot et al., COST-EFFECTIVENESS AND QUALITY-OF-LIFE ASSESSMENT OF GM-CSF AS AN ADJUNCT TO INTENSIVE REMISSION INDUCTION CHEMOTHERAPY IN ELDERLY PATIENTSWITH ACUTE MYELOID-LEUKEMIA, British Journal of Haematology, 100(4), 1998, pp. 629-636
INTERFERON-ALFA VERSUS CHEMOTHERAPY FOR CHRONIC MYELOID-LEUKEMIA - A METAANALYSIS OF 7 RANDOMIZED TRIALS
Authors: DELANNOY A KLUINNELEMANS JC LOUWAGIE A STRYCKMANNS P SUCIU S HEHLMANN R HEIMPEL H HASFORD J ZUFFA E BACCARANI M TURA S OHNISHI K OHNO R ALLAN N SHEPHERD P BROUSTET A ALISON R CLARKE M DUONG H GRAY R GREAVES E PETO R RICHARDS S SINCLAIR D WHEATLEY K
Citation: A. Delannoy et al., INTERFERON-ALFA VERSUS CHEMOTHERAPY FOR CHRONIC MYELOID-LEUKEMIA - A METAANALYSIS OF 7 RANDOMIZED TRIALS, Journal of the National Cancer Institute, 89(21), 1997, pp. 1616-1620
RESOURCE UTILIZATION IN INTENSIVE CHEMOTHERAPY, AUTOLOGOUS VERSUS ALLOGENEIC BONE-MARROW TRANSPLANTATION IN ACUTE MYELOID-LEUKEMIA
Authors: ZITTOUN RA MANDELLI F SUCIU S KEATING S DARDENNE M BERNEMAN Z DEWITTE T WILLEMZE R VANDERHEYDEN M
Citation: Ra. Zittoun et al., RESOURCE UTILIZATION IN INTENSIVE CHEMOTHERAPY, AUTOLOGOUS VERSUS ALLOGENEIC BONE-MARROW TRANSPLANTATION IN ACUTE MYELOID-LEUKEMIA, European journal of cancer, 33, 1997, pp. 64-64
NEW TRENDS IN THE TREATMENT OF ADULT ACUTE MYELOID-LEUKEMIA
Authors: WILLEMZE R SUCIU S MANDELLI F DEWITTE T AMADORI S HAYAT M PETTI MC SOLBU G ZITTOUN R
Citation: R. Willemze et al., NEW TRENDS IN THE TREATMENT OF ADULT ACUTE MYELOID-LEUKEMIA, European journal of cancer, 33, 1997, pp. 7-14
A RANDOMIZED PHASE-II STUDY ON THE EFFECTS OF 5-AZA-2'-DEOXYCYTIDINE COMBINED WITH EITHER AMSACRINE OR IDARUBICIN IN PATIENTS WITH RELAPSEDACUTE-LEUKEMIA - AN EORTC LEUKEMIA COOPERATIVE GROUP PHASE-II STUDY-(06893)
Authors: WILLEMZE R SUCIU S ARCHIMBAUD E MUUS P STRYCKMANS P LOUWAGIE EA BERNEMAN Z TJEAN M WIJERMANS P DOHNER H JEHN U LABAR B JAKSIC B DARDENNE M ZITTOUN R
Citation: R. Willemze et al., A RANDOMIZED PHASE-II STUDY ON THE EFFECTS OF 5-AZA-2'-DEOXYCYTIDINE COMBINED WITH EITHER AMSACRINE OR IDARUBICIN IN PATIENTS WITH RELAPSEDACUTE-LEUKEMIA - AN EORTC LEUKEMIA COOPERATIVE GROUP PHASE-II STUDY-(06893), Leukemia, 11, 1997, pp. 24-27
SYSTEMIC EFFECT OF INTRATHECAL METHOTREXATE DURING THE INITIAL PHASE OF TREATMENT OF CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA
Authors: THYSS A SUCIU S BERTRAND Y MAZINGUE F ROBERT A VILMER E MECHINAUD F BENOIT Y BROCK P FERSTER A LUTZ P BOUTARD P MARGUERITE G PLOUVIER E MICHEL G PLANTAZ D MUNZER M RIALLAND X CHANTRAINE JM NORTON L SOLBU G PHILIPPE N OTTEN J
Citation: A. Thyss et al., SYSTEMIC EFFECT OF INTRATHECAL METHOTREXATE DURING THE INITIAL PHASE OF TREATMENT OF CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA, Journal of clinical oncology, 15(5), 1997, pp. 1824-1830
GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR WITH INDUCTION TREATMENT OF ACUTE MYELOGENOUS LEUKEMIA - REPLY
Authors: ZITTOUN R CADIOU M SUCIU S
Citation: R. Zittoun et al., GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR WITH INDUCTION TREATMENT OF ACUTE MYELOGENOUS LEUKEMIA - REPLY, Journal of clinical oncology, 15(2), 1997, pp. 863-863
QUALITY-OF-LIFE IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA IN PROLONGED FIRST COMPLETE REMISSION AFTER BONE-MARROW TRANSPLANTATION (ALLOGENEIC OR AUTOLOGOUS) OR CHEMOTHERAPY - A CROSS-SECTIONAL STUDY OF THE EORTC-GIMEMA AML 8A TRIAL
Authors: ZITTOUN R SUCIU S WATSON M SOLBU G MUUS P MANDELLI F STRYCKMANS P PEETERMANS M THALER J RESEGOTTI L DARDENNE M WILLEMZE R
Citation: R. Zittoun et al., QUALITY-OF-LIFE IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA IN PROLONGED FIRST COMPLETE REMISSION AFTER BONE-MARROW TRANSPLANTATION (ALLOGENEIC OR AUTOLOGOUS) OR CHEMOTHERAPY - A CROSS-SECTIONAL STUDY OF THE EORTC-GIMEMA AML 8A TRIAL, Bone marrow transplantation, 20(4), 1997, pp. 307-315
USE OF RECOMBINANT GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR DURING AND AFTER REMISSION INDUCTION CHEMOTHERAPY IN PATIENTS AGED 61 YEARS AND OLDER WITH ACUTE MYELOID-LEUKEMIA (AML) - FINAL REPORT OF AML-11, A PHASE-III RANDOMIZED STUDY OF THE LEUKEMIA COOPERATIVE GROUP OFANIZATION-FOR-THE-RESEARCH-AND-TREATMENT-OF-CANCER (EORTC-LCG) AND THE DUTCH BELGIAN HEMATOONCOLOGY COOPERATIVE GROUP (HOVON)
Authors: LOWENBERG B SUCIU S ARCHIMBAUD E OSSENKOPPELE G VERHOEF GEG VELLENGA E WIJERMANS P BERNEMAN Z DEKKER AW STRYCKMANS P SCHOUTEN H JEHN U MUUS P SONNEVELD P DARDENNE M ZITTOUN R
Citation: B. Lowenberg et al., USE OF RECOMBINANT GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR DURING AND AFTER REMISSION INDUCTION CHEMOTHERAPY IN PATIENTS AGED 61 YEARS AND OLDER WITH ACUTE MYELOID-LEUKEMIA (AML) - FINAL REPORT OF AML-11, A PHASE-III RANDOMIZED STUDY OF THE LEUKEMIA COOPERATIVE GROUP OFANIZATION-FOR-THE-RESEARCH-AND-TREATMENT-OF-CANCER (EORTC-LCG) AND THE DUTCH BELGIAN HEMATOONCOLOGY COOPERATIVE GROUP (HOVON), Blood, 90(8), 1997, pp. 2952-2961
RANDOMIZED 3-ARM PHASE-III STUDY OF INTERLEUKIN-3 (IL-3), OR GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) AS AN ADJUVANT TO LOW-DOSES OF CYTOSINE-ARABINOSIDE (LD-ARAC) FOR THE TREATMENT OF HIGH-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS)/
Authors: GERHARTZ HH ZWIERZINA H SUCIU S WALTHER J DARDENNE M NEUWIRTOVA R FENAUX P BEKSAC M HAROUSSEAU JL LOUWAGIE A THYSS A FIERE D COIFFIER B BAUMELOU F LABAR B SOLBU G WILLEMZE R
Citation: Hh. Gerhartz et al., RANDOMIZED 3-ARM PHASE-III STUDY OF INTERLEUKIN-3 (IL-3), OR GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) AS AN ADJUVANT TO LOW-DOSES OF CYTOSINE-ARABINOSIDE (LD-ARAC) FOR THE TREATMENT OF HIGH-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS)/, Blood, 90(10), 1997, pp. 370-370
METAANALYSIS OF RANDOMIZED TRIALS COMPARING AUTOLOGOUS BMT (ABMT) VS CHEMOTHERAPY (CT) OR ABMT VS NO FURTHER TREATMENT (NFT) AS POSTREMISSION TREATMENT IN ADULT AML PATIENTS
Authors: SUCIU S
Citation: S. Suciu, METAANALYSIS OF RANDOMIZED TRIALS COMPARING AUTOLOGOUS BMT (ABMT) VS CHEMOTHERAPY (CT) OR ABMT VS NO FURTHER TREATMENT (NFT) AS POSTREMISSION TREATMENT IN ADULT AML PATIENTS, Blood, 90(10), 1997, pp. 492-492
MOLECULAR EVALUATION OF CONSOLIDATION THERAPY AND EARLY ALLOGRAFT OR AUTOGRAFT FOR BCR-ABL(POS) ADULT ACUTE LYMPHOBLASTIC-LEUKEMIA (ALL) PATIENTS - A PILOT-STUDY OF EIGLE (EUROPEAN INTERGROUP OF GIMEMA, FRENCHLALA AND EORTC)
Authors: STRYCKMANS P SUCIU S ANNINO L SAGLIO G MUUS P MARIE JP DOMBRET H GAMBERT J SOLBU G DARDENNE M MANDELLI F FIERE D
Citation: P. Stryckmans et al., MOLECULAR EVALUATION OF CONSOLIDATION THERAPY AND EARLY ALLOGRAFT OR AUTOGRAFT FOR BCR-ABL(POS) ADULT ACUTE LYMPHOBLASTIC-LEUKEMIA (ALL) PATIENTS - A PILOT-STUDY OF EIGLE (EUROPEAN INTERGROUP OF GIMEMA, FRENCHLALA AND EORTC), Blood, 90(10), 1997, pp. 809-809
AUTOLOGOUS BMT OR PSCT FOR PATIENTS WITH AML IN FIRST CR - A PRELIMINARY-ANALYSIS OF THE AML-10 STUDY OF THE LEUKEMIA COOPERATIVE GROUP (LCG) OF THE EORTC AND GIMEMA
Authors: KEATING S SUCIU S MANDELLI F DEWITTE T WILLEMZE R ARCHIMBAUD E HAYAT M ROTOLI B LABAR B RESEGOTTI L FAZI P DARDENNE M ZITTOUN R
Citation: S. Keating et al., AUTOLOGOUS BMT OR PSCT FOR PATIENTS WITH AML IN FIRST CR - A PRELIMINARY-ANALYSIS OF THE AML-10 STUDY OF THE LEUKEMIA COOPERATIVE GROUP (LCG) OF THE EORTC AND GIMEMA, Blood, 90(10), 1997, pp. 1034-1034
CYCLOSPORINE-A COMBINED WITH VAD VS VAD IN PATIENTS WITH REFRACTORY MULTIPLE-MYELOMA - AN EORTC HOVON RANDOMIZED PHASE-II STUDY/
Authors: SONNEVELD P SUCIU S WEIJERMANS P BEKSAC M NEUWIRTOVA R SOLBU G LOKHORST H VANDERLELIE J DOHNER H GERHARTZ H SEGEREN CM WILLEMZE R LOWENBERG B
Citation: P. Sonneveld et al., CYCLOSPORINE-A COMBINED WITH VAD VS VAD IN PATIENTS WITH REFRACTORY MULTIPLE-MYELOMA - AN EORTC HOVON RANDOMIZED PHASE-II STUDY/, Blood, 90(10), 1997, pp. 1590-1590
AUTOLOGOUS STEM-CELL TRANSPLANTATION FOR PATIENTS WITH POOR-RISK MDS AND SECONDARY AML (SAML) - A JOINT STUDY OF THE EORTC, EBMT, SAKK AND GIMEMA LEUKEMIA GROUPS
Authors: DEWITTE T SUCIU S VERHOEF G LABAR B ARCHIMBAUD E AUL C SELLESLAG D FERRANT A WIJERMANS P MANDELLI F AMADORI S JEHN U MUUS P DEMUYNCK H DARDENNE M ZITTOUN R WILLEMZE R GRATWOHL A APPERLEY J
Citation: T. Dewitte et al., AUTOLOGOUS STEM-CELL TRANSPLANTATION FOR PATIENTS WITH POOR-RISK MDS AND SECONDARY AML (SAML) - A JOINT STUDY OF THE EORTC, EBMT, SAKK AND GIMEMA LEUKEMIA GROUPS, Blood, 90(10), 1997, pp. 2594-2594
PROGNOSTIC VALUE OF TUBERCULIN AND BCG IMMUNOREACTIVITY IN STAGE-I HIGH-RISK MALIGNANT-MELANOMA (EORTC PROTOCOL-18781)
Authors: HENZ BM MACHER E BROCKER EB SUCIU S STEERENBERG PA JUNG E RUMKE P
Citation: Bm. Henz et al., PROGNOSTIC VALUE OF TUBERCULIN AND BCG IMMUNOREACTIVITY IN STAGE-I HIGH-RISK MALIGNANT-MELANOMA (EORTC PROTOCOL-18781), Dermatology, 193(2), 1996, pp. 105-109
Risultati: 1-25 | 26-50 | 51-64